NCT03233711 2026-03-18Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting344 enrolled
NCT04157985 2025-12-11Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsUniversity of PittsburghPhase 3 Completed161 enrolled